Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MultiHance vs Dotarem in Brain MRI (BENEFIT)
NCT02070380Phase 4Completed
- Sponsor
- Bracco Diagnostics Inc.
- Start
- Feb 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of gadobenate dimeglumine in brain tumor (4 arms), sponsored by Bracco Diagnostics Inc. Primary endpoint: Global Diagnostic Preference Between the Two Exams. Started Feb 2014; status: completed.
02
Drugs
gadobenate dimeglumine
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT02070380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070380.